Anvisa removes the revision of RDC 327/2019 from the Collegiate Board meeting agenda

The RDC No. 327/2019, which regulates cannabis products for medicinal purposes in Brazil, will not be updated in 2024. In the last Public Meeting of the Collegiate Board (Dicol) of the National Health Surveillance Agency (Anvisa), the revision of the RDC, proposed as item No. 8.28, was not included in the discussed agendas.

The update of the regulation, which aims to align the requirements with the latest scientific developments and the growing demands of the medicinal cannabis market in Brazil, is included in the Regulatory Agenda 2024-2025 and is expected for next year.

The end of the term of Antonio Barra Torres, the current Director-President of Anvisa, brings new perspectives for 2024. During the transition, the Reporting Director of item 8.28, Rômison Rodrigues Mota, will assume the position.